Evidence map›Paper›PMID 30056321›Full record

Trial reportDrug and alcohol dependence2018

A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study.

Taylor A Ochalek, Sarah H Heil, Stephen T Higgins, Gary J Badger, Stacey C Sigmon

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. HIV and Substance Use Disorders.Infectious disease clinics of North America · 2024
    Review
  6. Integrated Care Models: HIV and Substance Use.Current HIV/AIDS reports · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Taylor A OchalekVermont Center on Behavior and Health, University of Vermont, Rm 1415 UHC, 1 S. Prospect St., Burlington VT 05401, USA; Department of Psychology, University of Vermont, Rm 1415 UHC, 1 S. Prospect St., Burlington VT 05401, USA. Electronic address: tochalek@uvm.edu.
Sarah H HeilVermont Center on Behavior and Health, University of Vermont, Rm 1415 UHC, 1 S. Prospect St., Burlington VT 05401, USA; Department of Psychology, University of Vermont, Rm 1415 UHC, 1 S. Prospect St., Burlington VT 05401, USA; Department of Psychiatry, University of Vermont, Rm 1415 UHC, 1 S. Prospect St., Burlington VT 05401, USA.
Stephen T HigginsVermont Center on Behavior and Health, University of Vermont, Rm 1415 UHC, 1 S. Prospect St., Burlington VT 05401, USA; Department of Psychology, University of Vermont, Rm 1415 UHC, 1 S. Prospect St., Burlington VT 05401, USA; Department of Psychiatry, University of Vermont, Rm 1415 UHC, 1 S. Prospect St., Burlington VT 05401, USA.
Gary J BadgerDepartment of Biostatistics, University of Vermont, Biostatistics Unit, 27 Hills Building, Rm 25D, Burlington, VT 05401, USA.
Stacey C SigmonVermont Center on Behavior and Health, University of Vermont, Rm 1415 UHC, 1 S. Prospect St., Burlington VT 05401, USA; Department of Psychology, University of Vermont, Rm 1415 UHC, 1 S. Prospect St., Burlington VT 05401, USA; Department of Psychiatry, University of Vermont, Rm 1415 UHC, 1 S. Prospect St., Burlington VT 05401, USA.
University of Vermont · US

Funding

TRAINING IN BEHAV. PHARMACOLOGY OF HUMAN DRUG DEPENDENCET32DA007242 · NIDA · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI HEIL, SARAH H, HIGGINS, STEPHEN T · 1990 to 2025
$8.2M
Interim Buprenorphine Treatment to bridge waitlist delays: Stage II evaluationR01DA042790 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SIGMON, STACEY C · 2017 to 2021
$3.0M
Interim Treatment: Leveraging buprenophine + technology to bridge waitlist delaysR34DA037385 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SIGMON, STACEY C · 2014 to 2015
$652k
NIDA NIH HHS R01 DA042790NIDA NIH HHS R34 DA037385NIDA NIH HHS T32 DA007242
6 · The paper itself

Abstract

aimsThere is a critical need to reduce infectious disease transmission among individuals with opioid use disorder (OUD). Here we examine the ability of a novel, automated educational intervention, delivered via iPad in a single visit, to improve human immunodeficiency virus (HIV) and Hepatitis C (HCV) knowledge among adults with OUD.

methodsParticipants were 25 adults enrolled in a 12-week trial evaluating the efficacy of an Interim Buprenorphine Treatment for reducing illicit opioid use and other risk behaviors during delays to opioid treatment. Participants completed baseline HIV and HCV knowledge assessments with corrective feedback. They then completed an interactive HIV flipbook and HCV video followed by a second administration of the knowledge assessments. The knowledge assessments were repeated at post-intake Weeks 4 and 12.

resultsAt baseline, participants answered 69% and 65% of items correctly on the HIV and HCV assessments, respectively. The educational intervention was associated with significant increases in knowledge (86% and 86% correct on the HIV and HCV assessments, respectively; p's<.001). These improvements persisted throughout the study, with scores at Week 4 and 12 significantly greater than baseline (p's<.001).

conclusionThis HIV+Hepatitis Education intervention was associated with significant and sustained improvements in knowledge of HIV + HCV transmission and risk behaviors in this vulnerable group of individuals with OUD. Given the continuing opioid epidemic, efforts are urgently needed to reduce HIV and HCV contraction and transmission among individuals with OUD. Mobile health educational interventions may offer a time- and cost-effective approach for addressing these risks.

Indexed as

Health Knowledge, Attitudes, PracticeAdultAnalgesics, OpioidBuprenorphineFemaleHepatitis CHIV InfectionsHumansMaleMiddle AgedOpioid-Related DisordersPatient Education as TopicPilot ProjectsRisk-TakingTelemedicineAnalgesics, OpioidBuprenorphineHepatitis CHIVmobile healthOpioid agonist treatmentOpioid use disorderTechnology

Identifiers

PMID30056321
PMCPMC6446902
OpenAlexW2883819513

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.